Jorge FS Ferreira

Dr. Jorge FS Ferreira

Agricultural Water Efficiency and Salinity Research Unit (US Salinity Lab), Riverside, CA, USA
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2010 in Molecules
Verified
Journal Article
Open access
PDF file
Jorge FS FerreiraJorge FS Ferreira
Jorge FS Ferreira
DLDevanand L. Luthria
Devanand L. Luthria
TSTomikazu Sasaki
Tomikazu Sasaki
AHArne Heyerick
Arne Heyerick
Artemisia annua is currently the only commercial source of the sesquiterpene lactone artemisinin.Since artemisinin was discovered as the active component of A. annua in early 1970s, hundreds of papers have focused on the anti-parasitic effects of artemisinin and its semi-synthetic analogs dihydroartemisinin, artemether, arteether, and artesunate. Artemisinin per se has not been used in mainstream clinical practice due to its poor bioavailability when compared to its analogs. In the past decade, the work with artemisinin-based compounds has expanded to their anti-cancer properties. Although artemisinin is a major bioactive component present in the traditional Chinese herbal preparations (tea), leaf flavonoids, also present in the tea, have shown a variety of biological activities and may synergize the effects of artemisinin against malaria and cancer. However, only a few studies have focused on the potential synergistic effects between flavonoids and artemisinin. The resurgent idea that multi-component drug therapy might be better than monotherapy is illustrated by the recent resolution of the World Health Organization to support artemisinin-based combination therapies (ACT), instead of the previously used monotherapy with artemisinins. In this critical review we will discuss the possibility that artemisinin and its semi-synthetic analogs might become more effective to treat parasitic diseases (such as malaria) and cancer if simultaneously delivered with flavonoids. The flavonoids present in A. annua leaves have been linked to suppression of CYP450 enzymes responsible for altering the absorption and metabolism of artemisinin in the body, but also have been linked to a beneficial immunomodulatory activity in subjects afflicted with parasitic and chronic diseases.

1 August 2009 in Food Chemistry
Verified
Journal Article
Closed access
EBEbiamadon Andi Brisibe
Ebiamadon Andi Brisibe
UUUmoren E. Umoren
Umoren E. Umoren
FBFraideh Brisibe
Fraideh Brisibe
PMPedro M. Magalhäes
Pedro M. Magalhäes
Jorge FS FerreiraJorge FS Ferreira
Jorge FS Ferreira
RPRonald L. Prior
Ronald L. Prior

1 August 2005 in Plant Genetic Resources: Characterization and Utilization
Verified
Journal Article
Closed access
PDF file
Jorge FS FerreiraJorge FS Ferreira
Jorge FS Ferreira
JLJ. C. Laughlin
J. C. Laughlin
NDN. Delabays
N. Delabays
PMP.M. de Magalhães
P.M. de Magalhães
Malaria has been treated for over 350 years with quinine and quinine-derived drugs. However, in several areas of the world, some strains of the malarial parasitePlasmodium falciparumhave developed resistance against these drugs. Recently, the World Health Organization (WHO) recommended the use of artemisinin-combination treatments (ACT) as the first-line treatment for multidrug-resistant falciparum malaria. The WHO estimates that current supplies of artemisinin are sufficient for only 30 million ACT, and is foreseeing the need for 130–220 million ACT in 2005 (WHO, 2004). Current research on the production of synthetic artemisinin-like compounds by the Roll Back Malaria project, pharmaceutical companies and academia resulted in a promising synthetic artemisinin-like compound (OZ277) which is currently undergoing phase I clinical trials. In about 5 years this drug is expected to be approved and made available to the public, however, meeting current global demands for ACT depends on the immediate availability of affordable artemisinin-derived drugs. This will involve expansion of the area under cultivation ofArtemisia annuaand improved methods of cultivation and processing of raw material, associated with more efficient methods for extraction and purification of artemisinin from plant material. This review addresses the agricultural, environmental and genetic aspects that may be useful in the successful large-scale cultivation ofA. annuaand for producing the antimalarial artemisinin in areas where it is urgently needed today. It also includes geographic aspects (latitude and altitude), which will help make decisions about crop establishment in tropical countries, and includes a list of Good Agricultural and Collection Practices forA. annua.

1 December 2011 in Veterinary Parasitology
Verified
Journal Article
Closed access
LKL.M. Katiki
L.M. Katiki
ACAna Carolina de Souza Chagas
Ana Carolina de Souza Chagas
HBH.R. Bizzo
H.R. Bizzo
Jorge FS FerreiraJorge FS Ferreira
Jorge FS Ferreira
AAAlessandro Francisco Talamini Amarante
Alessandro Francisco Talamini Amarante

12 May 2011 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
Jorge FS FerreiraJorge FS Ferreira
Jorge FS Ferreira
PPPaul Peaden
Paul Peaden
JKJennifer Keiser
Jennifer Keiser

1 October 2011 in Journal of Dairy Science
Verified
Journal Article
Closed access
JTJ.A. Tekippe
J.A. Tekippe
AHA.N. Hristov
A.N. Hristov
KHK.S. Heyler
K.S. Heyler
TCT.W. Cassidy
T.W. Cassidy
VZV.D. Zheljazkov
V.D. Zheljazkov
GVG.A. Varga
G.A. Varga
A lactating cow trial was conducted to study the effects of dietary addition of oregano leaf material (Origanum vulgare L.; OV; 0, control vs. 500 g/d) on ruminal fermentation, methane production, total tract digestibility, manure gas emissions, N metabolism, organoleptic characteristics of milk, and dairy cow performance. Eight primiparous and multiparous Holstein cows (6 of which were ruminally cannulated) were used in a crossover design trial with two 21-d periods. Cows were fed once daily. The OV material was top-dressed and mixed with a portion of the total mixed ration. Cows averaged 80 ± 12.5 d in milk at the beginning of the trial. Rumen pH, concentration of total and individual volatile fatty acids, microbial protein outflow, and microbial profiles were not affected by treatment. Ruminal ammonia-N concentration was increased by OV compared with the control (5.3 vs. 4.3mM). Rumen methane production, which was measured only within 8h after feeding, was decreased by OV. Intake of dry matter (average of 26.6 ± 0.83 kg/d) and apparent total tract digestibly of nutrients did not differ between treatments. Average milk yield, milk protein, lactose, and milk urea nitrogen concentrations were unaffected by treatment. Milk fat content was increased and 3.5% fat-corrected milk yield tended to be increased by OV, compared with the control (3.29 vs. 3.12% and 42.4 vs. 41.0 kg/d, respectively). Fat-corrected (3.5%) milk feed efficiency and milk net energy for lactation (NE(L)) efficiency (milk NE(L) ÷ NE(L) intake) were increased by OV compared with the control (1.64 vs. 1.54 kg/kg and 68.0 vs. 64.4%, respectively). Milk sensory parameters were not affected by treatment. Urinary and fecal N losses, and manure ammonia and methane emissions were unaffected by treatment. Under the current experimental conditions, supplementation of dairy cow diets with 500 g/d of OV increased milk fat concentration, feed and milk NE(L) efficiencies, and tended to increase 3.5% fat-corrected milk yield. The sizable decrease in rumen methane production with the OV supplementation occurred within 8h after feeding and has to be interpreted with caution due to the large within- and between-animal variability in methane emission estimates. The OV was introduced into the rumen as a pulse dose at the time of feeding, thus most likely having larger effect on methane production during the period when methane data were collected. It is unlikely that methane production will be affected to the same extent throughout the entire feeding cycle.